<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>274</serviceExecutionTime><Trial id="124252"><TitleDisplay>Studies on the Relationship Between Aspiration Pneumonia and Substance P in Patients With ALS</TitleDisplay><TitleOfficial>Studies on the relationship between aspiration pneumonia and substance P in patients with ALS</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000005344</Identifier></Identifiers><Indications><Indication id="212">Motor neurone disease</Indication><Indication id="360">Pneumonia</Indication></Indications><BiomarkerNames><BiomarkerName id="4160" role="Disease marker" type="Genomic;Proteomic">Protachykinin-1</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1023605" type="Company"><TargetEntity id="4297607278" type="organizationId">National Hospital Organization</TargetEntity></SourceEntity><SourceEntity id="1082223" type="Company"><TargetEntity id="5039639698" type="organizationId">Hachinohe Hospital</TargetEntity></SourceEntity><SourceEntity id="212" type="ciIndication"><TargetEntity id="G12.2" type="ICD10"></TargetEntity><TargetEntity id="10028003" type="MEDDRA"></TargetEntity><TargetEntity id="D016472" type="MeSH"></TargetEntity><TargetEntity id="1290" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="360" type="ciIndication"><TargetEntity id="10035664" type="MEDDRA"></TargetEntity><TargetEntity id="D011014" type="MeSH"></TargetEntity><TargetEntity id="-104071315" type="omicsDisease"></TargetEntity><TargetEntity id="4597" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1023605">National Hospital Organization</Company><Company id="1082223">Hachinohe National Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Biomarker identification</Category></TrialCategories><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2011-03-01T00:00:00Z</DateStart><DateEnd type="actual">2017-10-03T00:00:00Z</DateEnd><DateChangeLast>2018-10-05T10:27:39Z</DateChangeLast><DateAdded>2013-04-26T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>National Hospital Organization Hachinohe National Hospital, Nursing section;  3-13-1 Fukiage, Hachinohe City, Aomori Prefecture, 031-0003, Japan</Affiliation><Name>Atsuko Ohi</Name><Phone>+81-22-717-7284</Phone></Contact><Contact type="Public contact"><Affiliation>Tohoku University Graduate School of Medicine, Department of Advanced Preventive Medicine for Infectious Disease;  2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan</Affiliation><Name>Mutsuo Yamaya</Name><Phone>+81-22-717-7184</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with ALS&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Concentrations of substance P</Description></Measure><Measure><Description>Bacteria in oral cavity</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Vital sign</Description></Measure><Measure><Description>Development of pneumonia</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this trial was to study the effects of substance P production and development of pneumonia in patients with amyotrophic lateral sclerosis (ALS) and to study the difference of substance P concentrations in patients with ALS complicated with or without aspiration pneumonia  [&lt;ulink linkType="Reference" linkID="1409393"&gt;1409393&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be observed for substance P production and development of pneumonia   [&lt;ulink linkType="Reference" linkID="1409393"&gt;1409393&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>National Hospital Organization Hachinohe Hospital</Name><Address1>Hachinohe</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000005344</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Motor neurone disease" id="17526"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pneumonia" id="16580"><Endpoint>Assessment of Disease Incidence</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pneumonia" id="16613"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pneumonia" id="16621"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Motor neurone disease" id="17517"><Endpoint>Assessment of Pulmonary Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Motor neurone disease" id="17523"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Motor neurone disease" id="17550"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pneumonia" id="15573"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Motor neurone disease" id="16084"><Criterion>Subjects with Clinical Diagnosis of ALS</Criterion></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2018-04-09T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-10-05T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="255089"><TitleDisplay>Arthroscopic Surgical Procedures versus Sham Surgery for Patients With Femoroacetabular Impingement and/or Labral Tears</TitleDisplay><TitleOfficial>Arthroscopic Surgical Procedures Versus Sham Surgery for Patients With Femoroacetabular Impingement and/or Labral Tears. A Multicenter, International, Double-blinded, Randomized, Controlled Trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02692807</Identifier><Identifier type="Secondary Organisational">2015091</Identifier><Identifier type="Other">NAR-1- 2016</Identifier><Identifier type="Trial Acronym">HIPARTI</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames><BiomarkerName id="46233" role="Therapeutic effect marker" type="Physiological">Hip motion</BiomarkerName><BiomarkerName id="49025" role="Therapeutic effect marker" type="Physiological">Hip strength</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Hip arthroscopic surgical procedure</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>diagnostic round</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1049414" type="Company"><TargetEntity id="5035526274" type="organizationId">Oslo University Hospital</TargetEntity></SourceEntity><SourceEntity id="1120538" type="Company"><TargetEntity id="4296506563" type="organizationId">Federation University Australia</TargetEntity></SourceEntity><SourceEntity id="20654" type="Company"><TargetEntity id="4296787491" type="organizationId">University of Ottawa</TargetEntity></SourceEntity><SourceEntity id="21852" type="Company"><TargetEntity id="4296055231" type="organizationId">La Trobe University</TargetEntity></SourceEntity><SourceEntity id="22182" type="Company"><TargetEntity id="5000698033" type="organizationId">University of Oxford</TargetEntity></SourceEntity><SourceEntity id="25208" type="Company"><TargetEntity id="5001165074" type="organizationId">Lund University</TargetEntity></SourceEntity><SourceEntity id="DOL1000133" type="Company"><TargetEntity id="5001204002" type="organizationId">Aarhus University</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1049414">Oslo University Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1120538">Federation University Australia</Company><Company id="20654">University of Ottawa</Company><Company id="21852">La Trobe University</Company><Company id="22182">University of Oxford</Company><Company id="25208">University of Lund</Company><Company id="DOL1000133">Aarhus University</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Surgical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>140</PatientCountEnrollment><DateStart>2016-02-29T00:00:00Z</DateStart><DateEnd type="estimated">2035-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-16T16:10:17Z</DateChangeLast><DateAdded>2016-03-09T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>m.a.risberg@nih.no</Email><Name>May Arna Risberg, PT, PhD</Name><Phone>4741312776</Phone></Contact><Contact type="Scientific contact"><Affiliation>Oslo University Hospital</Affiliation><Name>Lars Nordsletten, MD, PhD</Name></Contact><Contact type="Scientific contact"><Affiliation>Oslo University Hospital</Affiliation><Name>May Arna Risberg, PT, PhD</Name></Contact><Contact type="Public contact"><Email>agnethe.nilstad@nih.no</Email><Name>Agnethe Nilstad, PT, PhD</Name><Phone>4799224469</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Hip pain during daily and/or sporting activities&lt;/li&gt;&lt;li&gt;Intra-articular hip pain with radiological signs of FAI and/or labral tears eligible for hip arthroscopy (to be determined in a pragmatic fashion by the surgeon based on clinical examination and imaging&lt;/li&gt;&lt;li&gt;The patient is able to give written informed consent and to participate fully in the interventions and follow-up procedures&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pain that is not confirmed by physical examination of the hip&lt;/li&gt;&lt;li&gt;Evidence of preexisting osteoarthritis, defined as Tonnis grade&amp;gt; 1, or &amp;lt; 3 mm superior joint space width on AP pelvic radiograph&lt;/li&gt;&lt;li&gt;Center edge angle on radiograph&amp;lt; 25 degrees; previous known hip pathology such as Perthes' disease, slipped upper femoral epiphysis or avascular necrosis&lt;/li&gt;&lt;li&gt;Previous hip injury such as acetabular fracture, hip dislocation or femoral neck fracture&lt;/li&gt;&lt;li&gt;Previous hip surgery&lt;/li&gt;&lt;li&gt;Medical conditions complicating surgery (ASA 3); inflammatory joint disease (RA, Bechterew etc)&lt;/li&gt;&lt;li&gt;Physical inability to undertake testing procedures&lt;/li&gt;&lt;li&gt;Expected lack of compliance such as cognitive impairment, drug abuse or similar&lt;/li&gt;&lt;li&gt;Inability to understand the written and spoken language of the treatment center&lt;/li&gt;&lt;li&gt;Contra-indications to placebo surgery, which will include large loose body, chondral flap&amp;gt; 1 cm2 detached at three sides, complete labral radial flap tear and labral bucket-handle tear with complete avulsion &amp;gt; 1.5 cm long&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>International Hip Outcome Tool (IHOT-33): Patient-reported outcome measure (PRO)</Description><Timeframe>Baseline, 6, 12 and 24 months follow-ups; one year follow-up is main outcome</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>ASES Arthritis Self-Efficacy Scale: Self-Efficacy Scale questionnaire</Description><Timeframe>Baseline, 6, 12 and 24 months follow-ups</Timeframe></Measure><Measure><Description>Expectations of surgery: questionnaire</Description><Timeframe>Baseline</Timeframe></Measure><Measure><Description>HOOS - Hip Dysfunction and Osteoarthritis Outcome Score: patient-reported outcome measure (PRO) five subscales</Description><Timeframe>Baseline, 6, 12 and 24 months follow-ups-  only in some study sites</Timeframe></Measure><Measure><Description>Hip Sports Activity Scale (HSAS): activity Level (type)</Description><Timeframe>Baseline, 6, 12 and 24 months follow-ups</Timeframe></Measure><Measure><Description>Hip muscle strength: dynamometer</Description><Timeframe>Baseline, 6, 12 and 24 months follow-ups</Timeframe></Measure><Measure><Description>Measures of hip physical impairment: range of motion</Description><Timeframe>Baseline, 6, 12 and 24 months follow-ups</Timeframe></Measure><Measure><Description>Patient Spesific Functional Scale: patient report on three specific activities and their limitations</Description><Timeframe>Baseline, 6, 12 and 24 months follow-up</Timeframe></Measure><Measure><Description>Single leg squat performance: performance tests</Description><Timeframe>Baseline, 6, 12 and 24 months follow-ups</Timeframe></Measure><Measure><Description>Tampa scale of Kinesiophobia: fear of movement questionnaire</Description><Timeframe>Baseline, 6, 12 and 24 months follow-ups</Timeframe></Measure><Measure><Description>Total Hip Replacement: data from the Norwegian National Joint Registry on total hip joint arthroplasty (or similar registries from the other countries)</Description><Timeframe>1, 2, 5 and 10 years follow-up</Timeframe></Measure><Measure><Description>Work place Activity Limitation Survey (WALS): questionnaire (only for some of the study sites)</Description><Timeframe>Baseline, 6, 12 and 24 months follow-ups</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary aim of this study is to determine the efficacy of hip arthroscopic surgery      compared to a sham surgery (diagnostic arthroscopy only) for patients with symptomatic and      radiological findings related to impingement (FAI) and/or labral tears using a randomized,      controlled design.&lt;/para&gt;&lt;para&gt;Our main hypothesis is that surgical procedures of the hip will demonstrate greater efficacy      than sham surgery (diagnostic hip arthroscopy only) for hip related quality of life      (iHOT-33) after one year and at further (HIPARTI Study).&lt;/para&gt;&lt;para&gt;The secondary aim of this study is to establish modifiable risk factors associated with      pain, function, work participation and quality of life over one year in people aged 18 to 50      years with hip impingement and/or labral tears diagnosed at hip arthroscopy. (HARP Study: A      separate paper will be published with this main aim for the HARP Study). Long-term follow-ups      for HIPARTI Study as well as HARP Study will be performed at 2, 5 and 10 years).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;All patients with hip pain eligible for hip arthroscopy in our routine care pathways will be     included in the study. .The baseline assessment appointments will occur within 1 month of the initial approach.&lt;/para&gt;&lt;para&gt;Those who will not be willing to participate in the RCT (HIPARTI Study), will be asked if      interested in being included in a prospective longitudinal cohort study including similar      baseline and follow-up tests as those in the RCT (this will be the HARP Study with separate      papers published). All patients in the HARP Study will undergo hip arthroscopy surgery. The      Australian site will include most of their patients in the HARP Study, since the majority of      orthopedic surgeons working privately will not participate in the HIPARTI Study. &lt;/para&gt;&lt;para&gt;Randomization (HIPARTI) will occur prior to surgery, after final eligibility is confirmed.      Randomizations will be performed centrally using an automated computer generated system.      Block randomization and stratification for each center will be performed.&lt;/para&gt;&lt;para&gt;All patients will undergo imaging (which may include CT scan or at least 1.5 Tesla magnetic      resonance imaging MRI) prior to the surgical assessment as part of routine care. All      patients will also undergo standardized radiographs of the hips and pelvis also as part of      routine care. Plain radiographs will be examined for evidence of osteoarthritis as joint      space narrowing, osteophytes, cysts and subchondral hypertrophy. Several radiographical      measurements will be performed among them: the alpha angle and lateral center-edge angle      will be determined for the presence of FAI. Radiographs will also be part of follow-ups.&lt;/para&gt;&lt;para&gt;Participating orthopedic surgeons will be asked to coordinate their waiting lists to ensure      the hip arthroscopy patients are called for surgery in accordance with the study protocol.      Ideally, patients will complete their baseline assessment as close to the randomized      treatment as possible (within 1 months). In the event that surgery cannot be performed      within 1 month after baseline assessment, the same questions and assessments completed at      baseline will be completed again. The standard followed-ups at the 6 months and one year      include primary and secondary outcomes. One year is the primary end point where      randomization code will be broken according to a predefined published statistical protocol      (HIPARTI).&lt;/para&gt;&lt;para&gt;At all follow-ups the research coordinator/independent tester will attend. At the 6 month      follow-up an independent orthopedic surgeon will attend regularly and take care of patients      who are not satisfied. The aim is to use the following criteria as subjective complaint:      equal or worse than 10 points for the IHOT-33 score compared to baseline. &lt;/para&gt;&lt;para&gt;All patients (in both groups in the RCT (HIPARTI) as well as in the HARP study) will undergo      a postoperative rehabilitation program based on the best available evidence. Each patient      will be treated by physical therapists who will be trained and proficient in post-hip      arthroscopy rehabilitation. Rehabilitation will be delivered a minimum of eight sessions over      3-months and then once a month for the following 3 months. Details of rehabilitation are      outlined in Appendix Rehabilitation. This contains a treatment algorithm to guide clinical      reasoning and progression of treatment (manual therapy, exercises and education) through      weeks 1 to 12.&lt;/para&gt;&lt;para&gt;Long term follow-ups will be performed at 2, 5 and 10 years. Statistical analysis      procedures will be published and analysis performed prior to opening the group allocation      when all patients are included and followed through to the one year follow-up (main outcome).&lt;/para&gt;&lt;para&gt;Patients randomized to the HIPARTI study  will undergo the Hip arthroscopy surgical procedure or the sham procedure. Surgery will be  performed under general anesthesia.  Labrum may be debrided, sutured, detached and refixed if needed to treat a pincer lesion. Labrum will be  secured with suture anchors. Pincer and cam resection will be  performed using an arthroscopic burr. Cartilage lesions may be left untreated or treated with debridement or microfracture. Patients in the sham procedure will undergo the same arthroscopic procedures as stated above but no surgical interventions related to Cam, Pincer, or labral tear will be performed, only diagnostic round in the central and peripheral compartment will be  performed. Labrum, cartilage, and other possible conditions will be  looked for and findings will be  documented. Patients in the  Â prospective cohort (HARP study), that will not be willing to be included in the RCT (HIPARTI Study), will be asked if they will be willing to be included in the prospective cohort, or ongoing in countries will be only the surgery will be performed (Australia). They will sign an informed concent and will undergo surgical interventions as part of usual care. Outcomes collected and follow-ups will be the same as for the RCT (HIPARTI).&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Name>LaTrobe University, School Allied Health, College of Science, Helath and Engineering</Name><Address1>Melbourne</Address1><Address2>Victoria</Address2><Address3>3086</Address3><CountrySubDivision>Victoria</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>k.crossley@latrobe.edu.au</Email><Name>Kay Crossley, PT, PHD</Name><Phone>+61411055738</Phone></Contact><Contact type="Facility investigator"><Name>Joanne Kemp, PT, PHD</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Norway"><Sites><Site><Name>Division of Orthopedic Surgery, Oslo University Hospital</Name><Address1>Oslo</Address1><Address3>4956</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>s-loek@online.no</Email><Name>Sverre Loken, MD, PhD</Name><Phone>+4790704448</Phone></Contact><Contact type="Facility contact backup"><Email>tomcl@getmail.no</Email><Name>Tom Ludvigsen, MD</Name><Phone>+4790642130</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8413">Subjects with Somatic Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Osteoarthritis</Disease><PatientSegments><PatientSegment><PatientSegment id="8861">Subjects with Symptomatic Disease</PatientSegment><SubSegments><SubSegment id="8862">Subjects with pain&amp; stiffness</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02692807</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Osteoarthritis" id="13912"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Osteoarthritis" id="13889"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13898">Assessment of functional disability by Hip disability and Osteoarthritis Outcome Score (HOOS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="13912"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="28094">Assessment by Tampa Scale of Kinesiophobia (TSK)</SubEndpoint><SubEndpoint disease="Osteoarthritis" id="28113">Assessment by Arthritis Self-Efficacy Scale</SubEndpoint><SubEndpoint disease="Osteoarthritis" id="28194">Assessment by Work Limitation Questionnaire(WLQ)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="13927"><Endpoint>Assessment of Joint Structure/Function</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13931">Assessment of hip structure and function</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="13977"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26058"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="35052">Assessment by Tampa Scale of Kinesiophobia (TSK)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="44075"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13987">Assessment of muscle strength</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Osteoarthritis" id="14217"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14219">Subjects with history of/scheduled for hip arthroplasty</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22125"><Criterion>Subjects with Somatic Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22126">Subjects with joint pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="34191"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14194">Subjects with hip pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="34331"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14231">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34371"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22263">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="34871"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14230">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Osteoarthritis" id="11592"><Criterion>Subjects co-morbid with musculoskeletal diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11594">Subjects with disorders of hip joint</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="11602"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11631"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11634">Subjects with history of for hip surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="11645"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11649"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="20191">Osteoarthritis With Specific Clinical and Radiographic Presentation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="27907"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11655">Subjects unable to comply with protocol requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="27926"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="20184">Unwillingness to comply with protocol requirements</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-02-15T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-03-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="263648"><TitleDisplay>Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)</TitleDisplay><TitleOfficial>Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02805881</Identifier><Identifier type="Organisational Study">NRLF-BY531-CTIL</Identifier><Identifier type="Trial Acronym">CTO-TNS</Identifier></Identifiers><Indications><Indication id="4898">Major depressive disorder</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Neurolief system</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>combined trigeminal and occipital transcutaneous nerve stimulation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1100545" type="Company"><TargetEntity id="5043953372" type="organizationId">Neurolief Ltd</TargetEntity></SourceEntity><SourceEntity id="4898" type="ciIndication"><TargetEntity id="F33" type="ICD10"></TargetEntity><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="-1357758656" type="omicsDisease"></TargetEntity><TargetEntity id="54" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1100545">Neurolief Ltd</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2016-05-31T00:00:00Z</DateStart><DateEnd type="estimated">2019-05-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T00:32:54Z</DateChangeLast><DateAdded>2016-07-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>danielle.antler@BeerNess.HEALTH.GOV.IL</Email><Name>Danielle Antler</Name><Phone>+972 (8) 9258474</Phone></Contact><Contact type="Scientific contact"><Affiliation>Deputy Director, Beer- Yakov Nees-Ziona Mental Health Center</Affiliation><Name>Hilik Levkovitz, Prof.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;The subject is capable of understanding the study and to sign an informed consent&lt;/li&gt;&lt;li&gt;Subject is between the ages of 18 to 65 years old&lt;/li&gt;&lt;li&gt;Unipolar major depressive disorder&lt;/li&gt;&lt;li&gt;Score on the Hamilton Depression Rating Scale (HDRS21)&amp;gt; 22&lt;/li&gt;&lt;li&gt;Current MDD episode&amp;gt; 3 months&lt;/li&gt;&lt;li&gt;Nonresponse with&amp;gt; 6 weeks use of one to six antidepressant in current episode&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History of neurosurgical interventions&lt;/li&gt;&lt;li&gt;Subjects with metal implants or shrapnel in their head, except for dental implants&lt;/li&gt;&lt;li&gt;Skin lesion or inflammation at the region of the stimulating electrodes&lt;/li&gt;&lt;li&gt;Pregnancy or lactation&lt;/li&gt;&lt;li&gt;Women of reproductive age not using efficient contraceptive method&lt;/li&gt;&lt;li&gt;History of cerebrovascular event&lt;/li&gt;&lt;li&gt;Psychotic or bipolar depression&lt;/li&gt;&lt;li&gt;History of schizophrenia, schizoaffective disorder or other non-mood disorder psychosis&lt;/li&gt;&lt;li&gt;Current delirium, dementia, amnestic disorder or other cognitive disorders&lt;/li&gt;&lt;li&gt;Clinically significant current suicidal intent as assessed by the investigator team&lt;/li&gt;&lt;li&gt;Obsessive-compulsive disorder or post-traumatic stress disorder&lt;/li&gt;&lt;li&gt;Alcohol and non-alcohol psychoactive substance abuse or dependence&lt;/li&gt;&lt;li&gt;Significant cardiac, medical, or progressive neurological or medical illness&lt;/li&gt;&lt;li&gt;An implantable electrical device such as a pacemaker&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Incidence of Treatment-Emergent Adverse Events: safety measures will be recorded and evaluated at every evaluation visit. It will be coded using the Medical Dictionary for Regulatory Activities. Vital signs (blood pressure and pulse) will be assessed and documented at each evaluation visit</Description><Timeframe>6 weeks</Timeframe></Measure><Measure><Description>Hamilton Depression Rating Scale (HDRS21): change in the total score on the Hamilton Depression Rating Scale (HDRS21) from baseline (visit 1) to week 6 (visit 4)</Description><Timeframe>6 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study will be to assess       safety and feasibility of combined trigeminal and occipital transcutaneous nerve stimulation      (CTO-TNS) in major depressive disorder (MDD) patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will undergo treatment with the Neurolief system  applied by the patient at his home and/or surrounding daily during a period of 6 weeks.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Israel"><Sites><Site><Name>Beer- Yakov Nees-Ziona Mental Health Center</Name><Address1>Ness Ziona</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>danielle.antler@BeerNess.HEALTH.GOV.IL</Email><Name>Danielle Antler</Name><Phone>+972 (8) 9258474</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Depression</Disease><PatientSegments><PatientSegment><PatientSegment id="7449">Subjects with Major Depressive Disorder</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7458">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02805881</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Depression" id="10739"><Endpoint>Assessment of Depression Severity by Specific Criteria</Endpoint><SubEndpoints><SubEndpoint disease="Depression" id="10741">Assessment by Hamilton Depression Rating Scale (HDRS)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Depression" id="10781"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Depression" id="10805"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Depression" id="10818"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint><OtherEndpoint disease="Depression" id="34517"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Depression" id="10772">Assessment of feasibility/acceptability of therapy</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Depression" id="6402"><Criterion>Subjects with Major Depressive Disorder</Criterion></Inclusion><Inclusion disease="Depression" id="6432"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Depression" id="6436">Subjects with specified Hamilton depression rating score (HDRS)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6507"><Criterion>Subjects with Treatment Resistant Disease</Criterion></Inclusion><Inclusion disease="Depression" id="22450"><Criterion>Protocol Specified Duration of Depression/MDD</Criterion></Inclusion><Inclusion disease="Depression" id="34436"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Depression" id="6511">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Depression" id="8055"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Depression" id="8267">Subjects with psychotic depression</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8069"><Criterion>Subjects with Protocol Specified Clinical Manifestations</Criterion><SubCriteria><SubCriterion disease="Depression" id="8071">Subjects with cognitive impairment as a clinical manifestation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8086"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Depression" id="8089">Subjects co-morbid with schizophrenia</SubCriterion><SubCriterion disease="Depression" id="8091">Subjects with personality disorders</SubCriterion><SubCriterion disease="Depression" id="8092">Subjects with substance related disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8093"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Depression" id="8088">Subjects co-morbid with bipolar disorder</SubCriterion><SubCriterion disease="Depression" id="8094">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8095"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Depression" id="8102"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Depression" id="8138"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Depression" id="8141">Subjects with history of/scheduled for surgery for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8148"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Depression" id="8151">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="26984"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Depression" id="8152">Subjects without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-05-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-06-07T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-07-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="283552"><TitleDisplay>A study of the predictive value of early assessment after 1 cycle of induction chemotherapy with 18F-FDG PET/CT and diffusion-weighted MRI for response to radical chemoradiotherapy in head and neck squamous cell carcinoma</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="3673">Metastatic head and neck cancer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Fludeoxyglucose (18F)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Positron emmision/computed tomography (PET/CT)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1042032" type="Company"><TargetEntity id="5035525916" type="organizationId">National Institute for Health Research</TargetEntity></SourceEntity><SourceEntity id="1047852" type="Company"><TargetEntity id="5035525738" type="organizationId">Royal Marsden Hospital</TargetEntity></SourceEntity><SourceEntity id="14764" type="Company"><TargetEntity id="5035527038" type="organizationId">Biomedical Research Centre Ltd</TargetEntity></SourceEntity><SourceEntity id="3673" type="ciIndication"><TargetEntity id="5572" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1042032">National Institute for Health Research (NIHR)</Company><Company id="1047852">Royal Marsden Hospital</Company><Company id="14764">Biomedical Research Centre Ltd</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Diagnosis</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><PatientCountEvaluable>20</PatientCountEvaluable><DateChangeLast>2017-01-12T16:00:04Z</DateChangeLast><DateAdded>2017-01-12T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with stage III to IVa  locally advanced head and neck squamous cell carcinoma (HNSCC)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Response was assessed 3 monthyd after completion of chemoradiotherapy with clinical examination, MRI, and 18F-FDG PET/CT</Description></Measure><Measure><Description>Changes in functional and molecular imaging parameters after IC1 were compared between responders and nonresponders with the Mann-Whitney U test</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study was to assess the predictive value of early assessment (after 1 cycle of induction chemotherapy [IC]) with Fludeoxyglucose (18F) (18F-FDG) positron emission tomography/computed tomography (PET/CT) and diffusion-weighted (DW) MRI for subsequent response to radical chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC) [&lt;ulink linkType="Reference" linkID="1888696"&gt;1888696&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2016, results were published. After IC, significantly greater reduction in metabolic tumor volume (p = 0.03), total lesion glycolysis (p = 0.04) and tendency toward a larger but statistically non-significant increase in apparent diffusion coefficient were observed in responders than non-responders. There was no significant difference in the changes from baseline between the IC1 and IC2 for all functional and molecular imaging parameters, indicating that most biologic response to IC measured by 18F-FDG PET/CT and DW MRI was observed early after the first cycle of IC [&lt;ulink linkType="Reference" linkID="1888696"&gt;1888696&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients underwent 18F-FDG PET/CT diffusion-weighted (DW) MRI before and 2 week after each cycle of IC (first cycle, IC1; second cycle, IC2) [&lt;ulink linkType="Reference" linkID="1888696"&gt;1888696&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-01-12T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="284117"><TitleDisplay>A Pragmatic Trial of a Digital Health Intervention to Prevent Weight Gain in Primary Care</TitleDisplay><TitleOfficial>Balance: A Pragmatic Trial of a Digital Health Intervention to Prevent Weight Gain in Primary Care</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03003403</Identifier><Identifier type="Organisational Study">D0479</Identifier><Identifier type="Trial Acronym">Balance</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="330" role="Therapeutic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName><BiomarkerName id="332" role="Therapeutic effect marker" type="Physiological">Diastolic blood pressure</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>digital health intervention</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>usual care program</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20567" type="Company"><TargetEntity id="5000024231" type="organizationId">Duke University</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20567">Duke University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>443</PatientCountEnrollment><DateStart>2017-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2020-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-05-06T09:40:26Z</DateChangeLast><DateAdded>2017-01-11T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Duke University</Affiliation><Name>Dori M Steinberg, PhD, RD</Name></Contact><Contact type="Scientific contact"><Affiliation>Duke University</Affiliation><Name>Gary G Bennett, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients of Piedmont Health Services community health centers in central North Carolina only&lt;/li&gt;&lt;li&gt;BMI between 25 and 40 kg/m2 and weighs&amp;lt; 380 lbs&lt;/li&gt;&lt;li&gt;Speaks English or Spanish&lt;/li&gt;&lt;li&gt;Had a non-urgent outpatient visit at a participating community health center clinic at Piedmont Health Services  within the last 2 weeks&lt;/li&gt;&lt;li&gt;Has a cell phone&lt;/li&gt;&lt;li&gt;Willing to receive 3 to 12 study-related text messages per week&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Current Piedmont Health Services employee&lt;/li&gt;&lt;li&gt;Has past bariatric surgery or planned bariatric surgery (within next two years)&lt;/li&gt;&lt;li&gt;Diagnosed with cancer in the last 6 months and is in active treatment&lt;/li&gt;&lt;li&gt;Has a history of cardiovascular event (stroke/MI) in the last 12 months&lt;/li&gt;&lt;li&gt;Was hospitalized for a mental health issue in the last 12 months&lt;/li&gt;&lt;li&gt;Diagnosis of end stage renal disease&lt;/li&gt;&lt;li&gt;Currently participating in a weight loss program/research study&lt;/li&gt;&lt;li&gt;Plans to move out of area and not receive care within community health center network (within the next two years)&lt;/li&gt;&lt;li&gt;Currently or recently pregnant (within the last 6 months) - Females only&lt;/li&gt;&lt;li&gt;Currently or recently lactating (with the last 2 months)- Females only&lt;/li&gt;&lt;li&gt;Plans to get pregnant in the next 12 months - Females only&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in weight: the proportion of intervention arm participants who achieve weight maintenance (staying within 3% of baseline weight in kg) at 24 months post-randomization. This will be calculated as follows: ([baseline weight in kg - final weight at 24 months in kg]/baseline weight in kg]) x 100</Description><Timeframe>Baseline, 24 months post-randomization (up to 27 months to obtain 24 month data)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in Framingham risk score: average change in participant Framingham risk score at 24 months post-randomization, as measured by calculated 10-year Framingham risk score from the Framingham Heart Study</Description><Timeframe>Baseline, 24 months post-randomization (up to 27 months to obtain 24 month data)</Timeframe></Measure><Measure><Description>Change in blood pressure: average change in participant systolic and diastolic blood pressure at 24 months post-randomization, as measured in mmHg</Description><Timeframe>Baseline, 24 months post-randomization (up to 27 months to obtain 24 month data)</Timeframe></Measure><Measure><Description>Intervention cost-effectiveness: assess the intervention's incremental cost at 24 months post-randomization, defined as the cost-effectiveness ratio of cost in dollars/kg of weight maintained at 24 months, as compared to baseline weight in kg</Description><Timeframe>24 months post-randomization (up to 27 months to obtain 24 month data)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Balance is a pragmatic, randomized controlled effectiveness trial for      weight gain prevention for patients within rural community health centers, using a digital      health platform.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Balance will randomize overweight and obese adults who are participants      at a local community health center network (PiedmontÂ HealthÂ Services) to either: a 12-month weight gain prevention      intervention or usual care, or usual care. Intervention group components include tailored      behavior change goals; mHealth self-monitoring and feedback; skills training videos; and      stepped responsive coaching from clinic registered Dieticians. The usual care group will      receive standard primary care offered by their providers and automated text messages and      health information about maintaining a healthy weight. All intervention components and      materials will be provided in Spanish and English. The intervention utilizes the interactive obesity treatment approach, which creates an energy deficit by having participants achieve simple, straightforward, and concrete behavior change goals (eg, no fast food, no sugary drinks, walk 10,000 steps/day). Balance builds on the design and findings of the Shape study (&lt;ulink linkType="Protocol" linkID="185781"&gt;NCT00938535&lt;/ulink&gt;) to test a pragmatic intervention within rural community health centers. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Duke University - with Piedmont Health Services, Inc.</Name><Address1>Durham</Address1><Address2>North Carolina</Address2><Address3>27708</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7733">Overweight (pre-obese) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7734">Obese Class I Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7735">Obese Class II Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7752">Others</PatientSegment><SubSegments><SubSegment id="18680">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03003403</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20400">Assessment of Body Weight</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20597"><Endpoint>Assessment of Cardiovascular Risk Factors</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20599"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20554">Assessment of blood pressure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="29627"><Endpoint>Health Economic Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="29628">Assessment of cost effectiveness</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="29701"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19672"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22429">Obese Class I Subjects</SubCriterion><SubCriterion disease="Obesity" id="22430">Obese Class II Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19678"><Criterion>Subjects with Protocol Specified BMI</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19680">Subjects with BMI&gt;25</SubCriterion><SubCriterion disease="Obesity" id="19689">Subjects with BMI&lt;40</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19787"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22428">Overweight Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19790"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19798">Subjects able to communicate in the language specified in the protocol</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="34498"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19746">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="34819"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19792">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15293"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15294">Subjects co-morbid with stroke</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15295"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Obesity" id="15325"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15331">Subjects with neoplasm/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15335"><Criterion>Subjects with History of Surgical Procedures for Weight Loss</Criterion></Exclusion><Exclusion disease="Obesity" id="15364"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15368">Prior/Recent participating in clinical trial</SubCriterion><SubCriterion disease="Obesity" id="15373">Familial, geographical or social condition that would preclude study participation</SubCriterion><SubCriterion disease="Obesity" id="15390">Subjects with hospitalization for any cause</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="24974"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15397">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2018-12-17T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>22.58 Months</EnrollmentPeriod><EnrollmentRate>19.62 Patients/Month</EnrollmentRate><DateFirstReceived>2016-12-16T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-01-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-03-16T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-05-13T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change></ChangeHistory></Trial><Trial id="306994"><TitleDisplay>Evaluation of Two Types of Dental Implants in Lower Jaws</TitleDisplay><TitleOfficial>Rehabilitation of Posterior Atrophic Edentulous Mandibles with Prostheses Supported by 4 mm Long Implants or Longer Implants in Vertically Augmented Bone</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2015051122226N1</Identifier><Identifier type="Secondary Organisational">IR.TUMS.REC.1394.1798</Identifier></Identifiers><Indications></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Straumann SLActive implant (4SI, Straumann AG, Basel, Switzerland)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>Straumann implant in augmented bone (Straumann AG, Basel, Switzerland)</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1043016" type="Company"><TargetEntity id="5035525669" type="organizationId">Tehran University of Medical Sciences and Health Services</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1043016">Tehran University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>24</PatientCountEnrollment><DateStart>2016-04-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-01-01T00:00:00Z</DateEnd><DateChangeLast>2017-08-07T12:32:52Z</DateChangeLast><DateAdded>2017-08-07T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Dental Implant Research Center</Affiliation><Email>t-bitaraf@razi.tums.ac.irtaherehbitaraf@yahoo.com</Email><Name>Dr Tahereh Bitaraf</Name><Phone>00982188978351 00</Phone></Contact><Contact type="Scientific contact"><Affiliation>Dental Implant Research Center of Tehran University of Medical Sciences</Affiliation><Email>roknamir@sina.tums.ac.ir</Email><Name>Amirreza Rokn</Name><Phone>00982188978351 00</Phone></Contact><Contact type="Public contact"><Affiliation>Dental Implant Research Center</Affiliation><Email>t-bitaraf@razi.tums.ac.ir taherehbitaraf@yahoo.com</Email><Name>Dr Tahereh Bitaraf</Name><Phone>00982188978351</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;â©Bilateral edentulism in posterior mandible with a similar degree of bone atrophy on both â©sides requiring two to four dental implants&lt;/li&gt;&lt;li&gt;Vertical bone heights have to be 5 mm to 7.9 mm above the mandibular canals&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;General contraindications to implant surgery subjected to irradiation in the head and neck area -Immunosuppressed or immunocompromised&lt;/li&gt;&lt;li&gt;Treated or under treatment with intravenous amino-bisphosphonates&lt;/li&gt;&lt;li&gt;Untreated periodontitis&lt;/li&gt;&lt;li&gt;Poor oral hygiene and motivation&lt;/li&gt;&lt;li&gt;Uncontrolled diabetes&lt;/li&gt;&lt;li&gt;pPregnant or nursing&lt;/li&gt;&lt;li&gt;Substance abuse;&lt;/li&gt;&lt;li&gt;Psychiatric problems or unrealistic expectations&lt;/li&gt;&lt;li&gt;Lack of opposite occluding dentition in the area&lt;/li&gt;&lt;li&gt;Acute or chronic infection/inflammation in the area intended for implant placement&lt;/li&gt;&lt;li&gt;Extraction sites with less than 3 months of healing&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Peri-implant marginal bone level changes: intraoral radiographs</Description><Timeframe>At implant placement (6 months after GBR), at delivery of the prostheses (2 months after implantation), one year after loading</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Implant and prosthesis failures: observational</Description><Timeframe>During one year follow-up</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this RCT is to compare the outcome of partial fixed prostheses supported by 4-mm long implants (4SI, Straumann AG, Basel, Switzerland) with prostheses supported by implants of at least 10-mm long placed in posterior atrophic edentulous mandibles augmented with Guided bone regeneration (GBR) technique.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A total of 24 patients with bilateral atrophic mandibles having 5 to 7.9 mm bone height above the mandibular canal will be randomised according to a split-mouth design to receive two to four 4 mm long implants (4SI, Straumann AG, Basel, Switzerland) or at least 10-mm long implants (Straumann) in augmented bone. Mandibles will be vertically augmented with GBR, using combination of intraoral autogenous bone graft and allograft. Implants will be placed after 6 months. Patient will be followed for one year and outcome measures will be peri-implant marginal bone level changes, implant and prosthesis failures and any complication.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Dental Implant Research Center of Tehran University of Medical Sciences</Name><Address1>Tehran</Address1><Address2>Tehran</Address2><CountrySubDivision>Tehran</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Dr Tahereh Bitaraf</Name></Contact></Contacts></Site><Site><Name>Faculty of Dentistry of Tehran University of Medical Sciences</Name><Address1>Tehran</Address1><Address2>Tehran</Address2><CountrySubDivision>Tehran</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Dr Tahereh Bitaraf</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other mouth disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18265">Subjects with specific disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2015051122226N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other mouth disease" id="46482"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other mouth disease" id="46482"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other mouth disease" id="33061"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other mouth disease" id="35078"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other mouth disease" id="24056"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="24305"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="24629"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-08-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="314940"><TitleDisplay>Phenotypic Measurements and Their Relation to Disease Exacerbation in COPD Patients</TitleDisplay><TitleOfficial>Phenotypic Measurements and Their Relation to Disease Exacerbation in COPD Patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03300739</Identifier><Identifier type="Organisational Study">2016P002312</Identifier></Identifiers><Indications><Indication id="1185">Chronic obstructive pulmonary disease</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Disease marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="2713" role="Disease marker" type="Physiological">Forced expiratory volume</BiomarkerName><BiomarkerName id="10169" role="Disease marker" type="Physiological">Oxygen saturation</BiomarkerName><BiomarkerName id="10260" role="Disease marker" type="Physiological">Respiratory frequency</BiomarkerName><BiomarkerName id="12058" role="Disease marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="17697" role="Disease marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ResMed biomotion sensor (ResMed Sensor Technologies)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1118305" type="Company"><TargetEntity id="4297333628" type="organizationId">ResMed Corp</TargetEntity></SourceEntity><SourceEntity id="21569" type="Company"><TargetEntity id="4296541778" type="organizationId">Massachusetts Gen Hosp Pooled Pnsin Tr</TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"></TargetEntity><TargetEntity id="D029424" type="MeSH"></TargetEntity><TargetEntity id="-459670493" type="omicsDisease"></TargetEntity><TargetEntity id="277" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21569">Massachusetts General Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1118305">ResMed Corp</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2016-12-31T00:00:00Z</DateStart><DateEnd type="estimated">2018-05-31T00:00:00Z</DateEnd><DateChangeLast>2017-10-12T09:13:59Z</DateChangeLast><DateAdded>2017-10-12T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>yshin3@partners.org</Email><Name>Yunmi Shin</Name><Phone>617-643-0198</Phone></Contact><Contact type="Scientific contact"><Affiliation>MGH</Affiliation><Name>Stephen Agboola, MD</Name></Contact><Contact type="Public contact"><Email>ederedon@partners.org</Email><Name>Emily deRedon</Name><Phone>617-724-2155</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Medically stable and ambulatory COPD (primary diagnosis) patients who have had an emergency room visit or hospitalization for an acute exacerbation of COPD within the past 30 days&lt;/li&gt;&lt;li&gt;Sufficient understanding of the English language to be able to read and understand study procedures&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Currently on admission in the hospital, on non-invasive positive airway pressure ventilation&lt;/li&gt;&lt;li&gt;Visual, hearing or cognitive impairments at the discretion of their physician&lt;/li&gt;&lt;li&gt;Currently participating in a COPD telemonitoring program&lt;/li&gt;&lt;li&gt;No AT and T cellular coverage at their primary residence&lt;/li&gt;&lt;li&gt;Any other medical or psychological condition that, in the opinion of the investigator may present an unreasonable risk to the study participant as a result of his/her participation in this study, may make participant's participation unreliable, or may interfere with study assessments&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Respiratory rate (breaths per minute): collected by study device, Reassure respiration monitor. This device uses very low power radio waves to detect respiratory movements of a person while asleep</Description><Timeframe>Daily, 16 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Anxiety: collected via GAD-7 questionnaire</Description><Timeframe>Baseline (day 0) and close-out (16 weeks)</Timeframe></Measure><Measure><Description>Body Mass Index (kg/m[2]): Weight and height will be combined to report BMI</Description><Timeframe>Baseline (day 0) and close-out (16 weeks)</Timeframe></Measure><Measure><Description>COPD symptom assessment: collected via CAT questionnaire</Description><Timeframe>Weekly for 16 weeks</Timeframe></Measure><Measure><Description>Depression: collected via PHQ-8 questionnaire</Description><Timeframe>Monthly for 16 weeks</Timeframe></Measure><Measure><Description>Forced expiratory volume in 1 s (FEV1). FEV1 is the volume of air forcefully exhaled in 1 s: collected via spirometer</Description><Timeframe>Weekly for16 weeks</Timeframe></Measure><Measure><Description>Functional impairment due to dyspnea: collected via mMRC dyspnea scale</Description><Timeframe>Weekly for 16 weeks</Timeframe></Measure><Measure><Description>Hospitalization records: collected via electronic health record</Description><Timeframe>Baseline (day 0) and close-out (16 weeks)</Timeframe></Measure><Measure><Description>Medical treatment: collected via electronic health record</Description><Timeframe>Baseline (day 0) and close-out (16 weeks)</Timeframe></Measure><Measure><Description>Oxygen saturation (percentage): collected via pulse oximeter</Description><Timeframe>Daily for 16 weeks</Timeframe></Measure><Measure><Description>Physical activity: collected via step counts</Description><Timeframe>Daily for 16 weeks</Timeframe></Measure><Measure><Description>Quality of life: collected via SF-12 questionnaire</Description><Timeframe>Baseline (day 0) and close-out (16 weeks)</Timeframe></Measure><Measure><Description>Study device usability: collected via usability questionnaire</Description><Timeframe>Close-out (16 week)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This is an observational, pilot study focused on collecting data on clinical variables that      can improve the understanding of potential predictors of disease exacerbation and      readmissions in COPD patients. The study aim is to understand how the variability of clinical      parameters (respiratory rate, forced expiratory volume in one second, and oxygen saturation),      physical activity and quality of life is associated with the risk of exacerbation in COPD      patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with COPD diagnosis will be included and observed in this trial. The investigational product to be used in this trial will be the ResMed Biomotion Sensor (ResMed      Sensor Technologies, Dublin, Ireland).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Partners Connected Health</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02114</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>yshin3@partners.org</Email><Name>Yunmi Shin</Name><Phone>617-643-0198</Phone></Contact><Contact type="Facility contact backup"><Email>ederedon@partners.org</Email><Name>Emily deRedon</Name><Phone>617-724-2155</Phone></Contact><Contact type="Facility investigator"><Name>Geisler Benjamin, MD</Name></Contact><Contact type="Facility investigator"><Name>Jeff Liao, MD</Name></Contact><Contact type="Facility investigator"><Name>Stephen Agboola, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Chronic obstructive pulmonary disease</Disease><PatientSegments><PatientSegment><PatientSegment id="556">Subjects with Stable COPD</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="564">Subjects with disease related complications</PatientSegment><SubSegments><SubSegment id="565">Subjects with acute exacerbation of COPD/Infections</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03300739</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4540"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4550"><Endpoint>Assessment of Vital Signs</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4553">Respiratory rate</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4277"><Endpoint>Assessment of Forced Expiratory Volume in One Second (FEV1)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4336"><Endpoint>Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4344">Assessment of oxygen saturation (SaO2/SpO2)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4437"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4442">Dyspnea assessed by Medical Research Council Dyspnea Scale (MRCS)</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4463">Assessment by SF-36/SF-12</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="23913">COPD Assessment Test(CAT)Score</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="29403">Patient health questionnaire (PHQ)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4466"><Endpoint>Assessment of hospitalization</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4501"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4515">Physical activity by accelerometry </SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4540"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4567"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4572"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="44168"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4405">Assessment of BMI</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="44775"><Endpoint>Assessment of Clinical Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4485">Assessment of anxiety</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Chronic obstructive pulmonary disease" id="2060"><Criterion>Subjects with Diagnosis of COPD</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2064">Subjects with stable COPD</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2099"><Criterion>Subjects with Exacerbations</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2105">Subjects with severe exacerbation requiring hospitalization</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2171"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Chronic obstructive pulmonary disease" id="3112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3151"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="20268">Subjects with history of/scheduled for ventilatory support</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3239"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-02-28T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-08-23T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-10-12T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="364631"><TitleDisplay>Estrogen Receptor 1 Gene Polymorphism Frequency in Fibromyalgia Syndrome</TitleDisplay><TitleOfficial>Investigation of Estrogen Receptor 1 Gene Polymorphism Frequency in Patients With Fibromyalgia Syndrome</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03786393</Identifier><Identifier type="Organisational Study">NIGDE O.H.U.</Identifier></Identifiers><Indications><Indication id="2527">Fibromyalgia</Indication></Indications><BiomarkerNames><BiomarkerName id="5" role="Disease marker" type="Genomic;Proteomic">Estrogen receptor</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Genotyping</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>real-time PCR</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1178037" type="Company"><TargetEntity id="5064640740" type="organizationId">Nigde Omer Halisdemir Univesitesi</TargetEntity></SourceEntity><SourceEntity id="2527" type="ciIndication"><TargetEntity id="M79.7" type="ICD10"></TargetEntity><TargetEntity id="10048439" type="MEDDRA"></TargetEntity><TargetEntity id="D005356" type="MeSH"></TargetEntity><TargetEntity id="-1947347836" type="omicsDisease"></TargetEntity><TargetEntity id="1156" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1178037">Nigde Omer Halisdemir University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Cohort</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2019-03-11T00:00:00Z</DateStart><DateEnd type="estimated">2019-12-15T00:00:00Z</DateEnd><DateChangeLast>2019-03-14T09:20:03Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Assistant of Proffessor M.D. Ercan Kaydok, Nigde Omer Halisdemir University</Affiliation><Name>Ercan KAYDOK</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;As the inclusion criteria for the Fibromyalgia group:&lt;ul&gt;&lt;li&gt;Being between 18 and 60 years of age&lt;/li&gt;&lt;li&gt;Taking the diagnosis of primary FMS according to ACR 1990 diagnostic criteria&lt;/li&gt;&lt;li&gt;Accepting to participate in the study&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;As the inclusion criteria for the Control group:&lt;ul&gt;&lt;li&gt;Being between 18 and 60 years of age&lt;/li&gt;&lt;li&gt;Accepting to participate in the study&lt;/li&gt;&lt;li&gt;No diagnosis of fibromyalgia&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Having any sex hormone disease&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Polymorphism frequency: the frequency of estrogen receptor alpha polymorphism in fibromyalgia and control group</Description><Timeframe>9 month</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;In this      study, it is aimed to investigate whether there is a relationship between ESR-1 594G &amp;gt; A      (rs2228480) and ESR-1 325C &amp;gt; G (rs2295190) polymorphisms and fibromyalgia disease.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Methods: establishment of study groups: 100 subjects diagnosed as Fibromyalgia syndrome      according to the criteria of ACR 1990, 18 to 65 years old, and having similar sociodemographic      characteristics. 100 control subjects will be taken. As the inclusion criteria for the      subjects; Being between 18 and 60 years of age, taking the diagnosis of primary fibromyalgia Syndrome (FMS) according      to ACR 1990 diagnostic criteria, accepting to participate in the study, lack of any sex      hormone disease. The control group will be composed of subjects with similar age and gender      characteristics. The subjects taken into the control group will have no sex hormone. The      subjects will be informed about the subject before being taken into the study and the      necessary permits will be taken.&lt;/para&gt;&lt;para&gt;Semi-structured sociodemographic information form prepared by investigators will be used in accordance      with the clinical experience and the information obtained from the scanned sources and the      aims of the study (ANNEX-1) Age, gender, education level, marital status, BMI, family history      of fibromyalgia diseases and accompanying symptoms. Accompanied by the symptoms; TMD symptoms      such as migraine type headache, jaw pain and locking, sleep disorder, dry mouth, dry eyes,      irritable bowel symptoms, restless leg symptoms, soft tissue swelling, fatigue, depressive      symptoms or depression history will be questioned. Subjects with headache will be evaluated      by a neurologist in terms of the diagnosis of migraine. Pain evaluation of the cases will be      done by Visual Analog Scale (VAS). A 10 cm ruler will be used for this. Subjects will be      evaluated once and the appropriate amount of blood samples will be collected from the      patients after the evaluation.&lt;/para&gt;&lt;para&gt;Collection of blood samples: 5 ml blood samples from the control and subjects groups will be      taken into sterile, citrate tubes. The blood in the tubes will be stored at -80degC until      isolation of the DNA.&lt;br/&gt;Isolation of Genomic DNA: Genomic DNA will be isolated from the blood using a DNA isolation      kit. DNA purity will be determined by spectrophotometric method.&lt;/para&gt;&lt;para&gt;Genotyping: genotyping of ESR-1 325 C &amp;gt; G and 594 G &amp;gt; A polymorphisms in the study group will      be performed by using single nucleotide polymorphism analysis kit and sequence-specific      double-dye hydrolysis probes and allelic segregation analysis in real-time PCR using primers.      Genotyping of each subject and control will be repeated three times to ensure the reliability of      the analysis results.&lt;/para&gt;&lt;para&gt;Statistical methods: the number of individuals to be included in the study is determined by      Statistical Power Analysis. In this study, when alpha = 0.05, beta = 0.10, 1- beta = 0.90, it was      decided to take 100 individuals to each subjects and control groups, and the strength of the      test is found to be p = 0.9072. All data obtained from the study will be evaluated with SPSS      18 program. The X2 test and Student-t and Mann-Whitney tests will be used to evaluate the      suitability of nominal and continuous variables.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Turkey"><Sites><Site><Name>BOR Physical medicine and rehabilitaton hospital</Name><Address1>NiÄde</Address1><Address3>51000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>ercankaydok@ohu.edu.tr</Email><Name>Ercan KAYDOK, Ass. Proffessor</Name><Phone>+905056298408</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8413">Subjects with Somatic Pain</PatientSegment><SubSegments><SubSegment id="8415">Subjects with fibromyalgia</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="15301">Others</PatientSegment><SubSegments><SubSegment id="17337">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03786393</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="37192"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Pain" id="25906"><Endpoint>Assessment of Migraine/Other Headaches</Endpoint></OtherEndpoint><OtherEndpoint disease="Pain" id="26000"><Endpoint>Assessment of Pain</Endpoint></OtherEndpoint><OtherEndpoint disease="Pain" id="26014"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint><OtherEndpoint disease="Pain" id="26058"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint><OtherEndpoint disease="Pain" id="44746"><Endpoint>Assessment of Clinical Symptoms</Endpoint></OtherEndpoint><OtherEndpoint disease="Pain" id="44763"><Endpoint>Assessment of Physical Examination</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26010">Assessment of anthropometric measures</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Pain" id="46656"><Endpoint>Gene variants involved in outcome measures</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="48127">ESR1_HUMAN_rs2228480(A)</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22125"><Criterion>Subjects with Somatic Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22127">Subjects with fibromyalgia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Pain" id="34371"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22263">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34745"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22260">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34827"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22264">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-07-15T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-12-20T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="378980"><TitleDisplay>OFBIO study</TitleDisplay><TitleOfficial>Exploratory study of blood biomarkers to predict the therapeutic effect of nintedanib in idiopathic pulmonary fibrosis (IPF)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000036457</Identifier><Identifier type="Trial Acronym">OFBIO</Identifier></Identifiers><Indications><Indication id="3771">Idiopathic pulmonary fibrosis</Indication></Indications><BiomarkerNames><BiomarkerName id="1912" role="Therapeutic effect marker" type="Physiological">Forced Vital Capacity</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>nintedanib</Name><Drug id="51160">nintedanib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="51160">nintedanib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1071357">Chiba University Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="51160" type="Drug"><TargetEntity id="379939" type="siDrug">Nintedanib</TargetEntity></SourceEntity><SourceEntity id="1071357" type="Company"><TargetEntity id="5037635967" type="organizationId">Chiba University Hospital</TargetEntity></SourceEntity><SourceEntity id="3771" type="ciIndication"><TargetEntity id="J84.112" type="ICD10"></TargetEntity><TargetEntity id="10021240" type="MEDDRA"></TargetEntity><TargetEntity id="D054990" type="MeSH"></TargetEntity><TargetEntity id="2032" type="ORPHANET"></TargetEntity><TargetEntity id="-1110748304" type="omicsDisease"></TargetEntity><TargetEntity id="289" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="168" type="Action"><TargetEntity id="1105" type="Mechanism">FGFR Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1722" type="Action"><TargetEntity id="1103" type="Mechanism">VEGFR Inhibitors</TargetEntity><TargetEntity id="1619" type="Mechanism">Anti-VEGF</TargetEntity><TargetEntity id="1788" type="Mechanism">Vascular Endothelial Growth Factor (VEGF) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3154" type="Action"><TargetEntity id="2314" type="Mechanism">CSF1R (c-FMS) Inhibitors</TargetEntity><TargetEntity id="4836" type="Mechanism">Anti-Colony Stimulating Factor 1 Receptor (CSF1R)</TargetEntity><TargetEntity id="4956" type="Mechanism">Anti-M-CSF</TargetEntity></SourceEntity><SourceEntity id="3576" type="Action"><TargetEntity id="1073" type="Mechanism">Src Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3584" type="Action"><TargetEntity id="1465" type="Mechanism">Lck Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3586" type="Action"><TargetEntity id="1528" type="Mechanism">Lyn Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3682" type="Action"><TargetEntity id="2298" type="Mechanism">FGFR1 Inhibitors</TargetEntity><TargetEntity id="4080" type="Mechanism">Anti-FGFR1</TargetEntity></SourceEntity><SourceEntity id="3685" type="Action"><TargetEntity id="2243" type="Mechanism">FGFR2 Inhibitors</TargetEntity><TargetEntity id="4378" type="Mechanism">Anti-FGFR2</TargetEntity></SourceEntity><SourceEntity id="3688" type="Action"><TargetEntity id="1702" type="Mechanism">FGFR3 Inhibitors</TargetEntity><TargetEntity id="3639" type="Mechanism">Anti-FGFR3</TargetEntity></SourceEntity><SourceEntity id="3806" type="Action"><TargetEntity id="1628" type="Mechanism">Flt3 (FLK2/STK1) Inhibitors</TargetEntity><TargetEntity id="1910" type="Mechanism">Anti-CD135 (flt-3)</TargetEntity></SourceEntity><SourceEntity id="3846" type="Action"><TargetEntity id="1308" type="Mechanism">VEGFR-1 (Flt-1) Inhibitors</TargetEntity><TargetEntity id="2609" type="Mechanism">Anti-VEGFR-1 (Flt-1)</TargetEntity></SourceEntity><SourceEntity id="3848" type="Action"><TargetEntity id="1309" type="Mechanism">VEGFR-2 (FLK-1/KDR) Inhibitors</TargetEntity><TargetEntity id="1786" type="Mechanism">Anti-VEGFR-2 (KDR)</TargetEntity></SourceEntity><SourceEntity id="3850" type="Action"><TargetEntity id="1627" type="Mechanism">VEGFR-3 (FLT4) Inhibitors</TargetEntity><TargetEntity id="2518" type="Mechanism">Anti-VEGFR-3 (FLT4)</TargetEntity></SourceEntity><SourceEntity id="48489" type="Action"><TargetEntity id="1650" type="Mechanism">PDGFRalpha Inhibitors</TargetEntity><TargetEntity id="2517" type="Mechanism">Anti-CD140a (PDGFRalpha)</TargetEntity><TargetEntity id="5666" type="Mechanism">PDGFRalpha (Asp842Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="48492" type="Action"><TargetEntity id="1651" type="Mechanism">PDGFRbeta Inhibitors</TargetEntity><TargetEntity id="1831" type="Mechanism">Anti-CD140b (PDGFRbeta)</TargetEntity></SourceEntity><SourceEntity id="948" type="Action"><TargetEntity id="1072" type="Mechanism">PDGFR Family Inhibitors</TargetEntity><TargetEntity id="1789" type="Mechanism">Platelet-Derived Growth Factor (PDGF) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1071357">Chiba University Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="168">FGF receptor antagonist</Action><Action id="1722">VEGF receptor antagonist</Action><Action id="3154">CSF-1 antagonist</Action><Action id="3576">Src tyrosine kinase inhibitor</Action><Action id="3584">Lck tyrosine kinase inhibitor</Action><Action id="3586">Lyn tyrosine kinase inhibitor</Action><Action id="3682">FGF1 receptor antagonist</Action><Action id="3685">FGF2 receptor antagonist</Action><Action id="3688">FGF3 receptor antagonist</Action><Action id="3806">Flt3 tyrosine kinase inhibitor</Action><Action id="3846">VEGF-1 receptor antagonist</Action><Action id="3848">VEGF-2 receptor antagonist</Action><Action id="3850">VEGF-3 receptor antagonist</Action><Action id="48489">PDGF receptor alpha antagonist</Action><Action id="48492">PDGF receptor beta antagonist</Action><Action id="948">PDGF receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2953">Anti-inflammatory</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="664">Fibrosuppressant</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2019-04-01T00:00:00Z</DateStart><DateChangeLast>2019-05-06T11:36:18Z</DateChangeLast><DateAdded>2019-05-03T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Chiba University Hospital ; Respiratory medicine </Affiliation><Email>mthrsgnm@chiba-u.jp</Email><Name>MITSUHIRO ABE</Name><Phone>043-226-2576</Phone></Contact><Contact type="Scientific contact"><Affiliation>Chiba University Hospital ; Respiratory medicine </Affiliation><Email>mthrsgnm@chiba-u.jp</Email><Name>MITSUHIRO ABE</Name><Phone>043-226-2576</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients diagnosed with IPF according to 2018 ATS / ERS / JRS / ALAT guidelines&lt;/li&gt;&lt;li&gt;Patients &gt; 20 years old&lt;/li&gt;&lt;li&gt;Patients with %FVC&amp;lt; 80% at entry time or patients with decrease of %FVC  &gt; 3% in the past 6 months&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who can not get consent&lt;/li&gt;&lt;li&gt;Patients whom the doctor in charge deems inappropriate&lt;/li&gt;&lt;li&gt;Patients with acute exacerbation at time&lt;/li&gt;&lt;li&gt;Patients with malignancy&lt;/li&gt;&lt;li&gt;Patients scheduled for surgery within 6 months&lt;/li&gt;&lt;li&gt;Patients with severe liver disorder (Child-Pugh B or more)&lt;/li&gt;&lt;li&gt;Patients whose prognosis is predicted to be&amp;lt; 6 months&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Decrease of % FVC</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Adverse event</Description></Measure><Measure><Description>Overall survival</Description></Measure><Measure><Description>Symptoms</Description></Measure><Measure><Description>Treatment continuation rate</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to search for factors that predict the therapeutic effect of &lt;ulink linkType="Drug" linkID="51160"&gt;nintedanib&lt;/ulink&gt; using serum and plasma samples of idiopathic pulmonary fibrosis patients who receive nintedanib. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients who received nintedanib will be included and observed. Investigators will perform a statistical analysis for biomarker changes before and after treatment with the Wilcoxon test.Â As a secondary study, they will also examine factors affecting symptoms, pulmonary function and HRCT findings at 12 months. Prognostic factors are also examined from the final outcome and survival time.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Chiba University Hospital</Name><Address1>Chiba</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Interstitial lung disease</Disease><PatientSegments><PatientSegment><PatientSegment id="11997">Subjects with Idiopathic Interstitial Lung Disease</PatientSegment><SubSegments><SubSegment id="11372">Subjects with Idiopathic Pulmonary Fibrosis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000036457</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Interstitial lung disease" id="22153"><Endpoint>Assessment of Forced Vital Capacity (FVC)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Interstitial lung disease" id="22163"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Interstitial lung disease" id="22170"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Interstitial lung disease" id="22195"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Interstitial lung disease" id="22196"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Interstitial lung disease" id="22214"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Interstitial lung disease" id="22208"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Interstitial lung disease" id="19604"><Criterion>Subjects with Idiopathic Pulmonary Fibrosis(IPF)</Criterion></Inclusion><Inclusion disease="Interstitial lung disease" id="35632"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Interstitial lung disease" id="17309"><Criterion>Subjects with Complications of ILD</Criterion><SubCriteria><SubCriterion disease="Interstitial lung disease" id="17311">Subjects with exacerbation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Interstitial lung disease" id="17318"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Interstitial lung disease" id="17326">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Interstitial lung disease" id="17355"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Interstitial lung disease" id="25560"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Interstitial lung disease" id="25905"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Interstitial lung disease" id="17327">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Interstitial lung disease" id="26892"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-05-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="96912"><TitleDisplay>Thermal Ablation in Larger Liver and Kidney Tumors</TitleDisplay><TitleOfficial>Thermal Ablation With a Loosely Wound Helical Coil for Radiofrequency Treatment of Large Renal and Hepatic Tumors in Patients Undergoing Partial or Total Nephrectomy or Heptectomy</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">RFA</Identifier><Identifier type="NCT">NCT01720706</Identifier></Identifiers><Indications><Indication id="3462">Metastatic liver cancer</Indication><Indication id="999">Renal tumor</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>RFA loosely wound thermal coil (University Health Network)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="28443" type="Company"><TargetEntity id="4296791312" type="organizationId">University Health Network</TargetEntity></SourceEntity><SourceEntity id="3462" type="ciIndication"><TargetEntity id="10055110" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="999" type="ciIndication"><TargetEntity id="C64" type="ICD10"></TargetEntity><TargetEntity id="10038389" type="MEDDRA"></TargetEntity><TargetEntity id="D007680" type="MeSH"></TargetEntity><TargetEntity id="-1866040075" type="omicsDisease"></TargetEntity><TargetEntity id="607" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="28443">The University Health Network</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>12</PatientCountEnrollment><DateStart>2011-08-31T00:00:00Z</DateStart><DateEnd type="actual">2017-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-05-22T11:26:54Z</DateChangeLast><DateAdded>2012-11-08T03:18:46Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University Health Network, Toronto</Affiliation><Name>Michael Jewett, M.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects with a solid renal mass who are undergoing partial or radical nephrectomy&lt;/li&gt;&lt;li&gt;Subjects with a solid hepatic masses of heptacellular carcinoma or metastatic liver&#xa;             tumor booked for partial or radical hepatectomy&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Irreversible coagulation defects&lt;/li&gt;&lt;li&gt;Hepatic infection&lt;/li&gt;&lt;li&gt;No extra hepatic malignant disease&lt;/li&gt;&lt;li&gt;Venous invasion and/or&lt;/li&gt;&lt;li&gt;Morbid obesity&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>RF electrodes can be accurately and safely placed in the desired location: this will be assessed during the surgery and once the tumor is removed and examined</Description><Timeframe>Up to 10 days prior to surgery and up to 24 h after surgery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The safety of energy application with the RF coil device including assessing effect on surrounding liver tissue: this will be assessed during the surgery and once the tumor is removed and examined</Description><Timeframe>Up to 10 days prior to surgery and up to 24 h after surgery</Timeframe></Measure><Measure><Description>Verifying that large (&gt; 2 cm) liver tumors are effectively ablated with RF energy: once the tumor is removed, the ablation field can be fully examined</Description><Timeframe>Up to 24 h after surgery</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was  to determine the safety and efficacy of the&#xa;      application of a unique interstitial radio frequency thermal therapy for the treatment of&#xa;      large tumors in the kidney or liver.  The novel device offers subjects a more effective&#xa;      therapy than conventional radiofrequency ablation (RFA by &lt;ulink linkType="Company" linkID="28443"&gt;University Health Network&lt;/ulink&gt;) and for subjects with large tumors fewer number of treatments&#xa;      and  needle insertion sites. The clinical treatment volumes (or sites of focal tumors) would&#xa;      be determined by a combination of biopsy and contrast enhanced CT imaging.&#xa; &lt;/para&gt;&lt;para&gt;The study would assess if novel device can produce lesions in the liver or kidney in a&#xa;      controlled and predictable manner and with sufficient size to effectively manage disease&#xa;      progression in the organ. The extent of lesion size at a delivered power setting and&#xa;      treatment time would be measured with post-treatment CT or MRI and biopsy as measures of&#xa;      tissue response.&lt;/para&gt;&lt;para&gt;Hypothesis&lt;br/&gt;Interstitial thermal therapy in the form of RF energy delivered percutaneously under US or CT guidance with our newly developed novel coil electrode is a safe and effective method to ablate large renal and hepatic tumors. This is an alternative to immediate surgery or to surveillance with possible delayed treatment.&lt;/para&gt;&lt;para&gt;Objectives:&lt;br/&gt;To use the novel RF device and technique in liver tumor as developed in the porcine model to patients with heptacellular carcinoma by:&lt;br/&gt;Establishing that RF electrodes can be accurately and safely placed in the desired location.&lt;br/&gt;Establish the safety of energy application with the RF coil device including assessing effect on surrounding liver tissue.&lt;br/&gt;Verifying that large (&gt; 2 cm) liver tumors are effectively ablated with RF energy.&lt;br/&gt;Establish the safety of energy application with the RF coil device including assessing effect on surrounding kidney tissue.&lt;br/&gt;To apply the novel RF device and technique in kidney tumor ablation as developed in the porcine model to patients with renal cell carcinoma by:&lt;br/&gt;Establishing that RF electrodes can be accurately and safely placed in the desired location.&lt;br/&gt;Verifying that large (RFA Loosely wound thermal coil2cm) kidney tumors are effectively ablated with RF energy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this study there would be two arms:&lt;br/&gt;Arm 1: the RFA Loosely wound thermal coil electrode would be inserted directly or percutaneously into the lesion, depending on the imaging modality (US or CT guidance) and deployed with same method as previously described in the 'delayed arm'. Energy would be delivered using the single timed heating cycle. Treatment would be monitored with B mode US. Once the cycle was completed, the probe would be removed and the planned surgery would continue with partial or radical nephrectomy.&lt;br/&gt;Arm 2:  using an electrically insulated 12ga introducer with trocar was inserted percutaneously into the renal tumor. The needle tip would be placed 20 mm from the center of the target. The trocar is removed and co-axially (ie, within the introducer), a core biopsy of the lesion was performed with a 14 to 18 gauge needle. The radiofrequency applicator with a 14ga cannula containing the RFA Loosely wound thermal coil electrode was then optimally positioned and locked into the introducer. On approximately day 6 to 10, a partial or radical nephrectomy would be performed in the usual way.&lt;/para&gt;&lt;para&gt;For subject that have an ultrasound guided procedure, the RFA procedure would be done in the routine operating room in an open fashion, the kidney would be exposed surgically in the usual way in anticipation of the partial or radical nephrectomy. The kidney tumour would be located by gross inspection, palpation and with the aid of intraoperative US if required. In this case, the RFA probe would be inserted directly into the lesion. For those subjects that have a CT guided procedure along with US, the procedure would be done in the MPOR and the RFA probe would be inserted percutaneously into the lesion, prior to opening and exposing the kidney. If the surgery was unable to be performed in the MPOR, the subject would transferred to a routine operating room, while under general anesthetic, to have their surgery. They would be accompanied by the anesthesiologist.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>University Health Network</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><Address3>M5g 2M9</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hepatobiliary system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8059">Subjects with Advanced/Metastatic Primary Liver Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Cancer supportive care</Disease><PatientSegments><PatientSegment><PatientSegment id="9010">Solid tumor subjects for supportive care</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01720706</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Renal cell carcinoma" id="10650"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Renal cell carcinoma" id="10665">Assessment of procedure related complications</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Renal cell carcinoma" id="10650"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Renal cell carcinoma" id="10665">Assessment of procedure related complications</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Hepatobiliary system tumor" id="12055"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hepatobiliary system tumor" id="12117"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Renal cell carcinoma" id="6332"><Criterion>Subjects co-morbid with malignancy/tumor</Criterion></Inclusion><Inclusion disease="Renal cell carcinoma" id="6342"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7830"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7872"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="7878">Subjects with history of surgery/procedure for hepato-biliary cancer</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Renal cell carcinoma" id="7858"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Renal cell carcinoma" id="7909"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Renal cell carcinoma" id="7910"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="9406"><Criterion>Subjects with Secondary Metastasis to Liver</Criterion></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="9412"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10881"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10882"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-10-29T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-11-08T03:18:46Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2019-05-22T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-05-22T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-22T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>